Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Middle East News Digest.
Press releases published on August 6, 2025
Steel Market Set to Soar, Anticipated to Achieve USD 1,200 Billion by 2035| At 1.96% CAGR
EIN Presswire
·
August 6, 2025
The Steel Market is projected to grow USD 1,200 billion by 2035, registering a compound annual growth rate CAGR of 1.96% during the forecast period till 2035 BERLIN, GERMANY, August 6, 2025 /EINPresswire.com/ -- Steel is one of the most important …
Textile Chemicals Market Set to Reach USD 36.26 Billion, with a Healthy 4.50% CAGR Till Forecasts 2030
EIN Presswire
·
August 6, 2025
The textile chemicals market growth is expected to rise to a CAGR of 4.5%, with a value of USD 36.26 billion by the end of 2030. NEW YORK, NY, UNITED STATES, August 6, 2025 /EINPresswire.com/ -- The textile chemicals market plays a pivotal role in the …
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
August 6, 2025
MALVERN, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from …
Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire
·
August 6, 2025
SEATTLE, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that it has commenced an underwritten public offering of $75.0 …
BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates
GlobeNewswire
·
August 6, 2025
Oral NLRP3 inhibitor BGE-102 on track for Phase 1 initiation in 2H 2025 with initial data by year-end Expanded APJ agonist pipeline through option agreement for novel antibody and advancement of proprietary oral small molecules Strengthened discovery …
Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 6, 2025
Enrollment Complete in Cohorts 1 and 2 of MyPEAK™-1 Phase 1b/2 Trial of TN-201 for MYBPC3-associated HCM; Positive DSMB Safety Review Enables Enrollment of Expansion Cohorts Cohort 1 of RIDGE™-1 Phase 1b Trial of TN-401 Enrolled and First PKP2-associated …
Daity by Mohsen Koofiani Wins Bronze in A' Packaging Design Awards
EIN Presswire
·
August 6, 2025
Mohsen Koofiani's Innovative Packaging Design for Daity Fruit Ice Lollies Recognized with Prestigious A' Design Award COMO, CO, ITALY, August 6, 2025 /EINPresswire.com/ -- The A' Design Award, a highly respected and well-recognized award in the field of …
Keros to Exclusively Prioritize the Clinical Advancement of KER-065
GlobeNewswire
·
August 6, 2025
Company Discontinuing Development of Cibotercept (KER-012) Announces Board and Leadership Changes Designed to Support Streamlined Operational Structure and Strategic Realignment LEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. …
Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results
GlobeNewswire
·
August 6, 2025
CTIM-76 and CT-95 Phase 1 dose-escalation studies ongoing Cash and cash equivalents of $83.5 million as of June 30, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, Aug. 06, 2025 (GLOBE NEWSWIRE) …
Guildhall Named Best Executive Search & Recruitment Agency in UAE for 2025
EIN Presswire
·
August 6, 2025
Guildhall’s data-driven, AI-optimised hiring model earns top honours, cementing its status as the best recruitment agency in Dubai and across the UAE. DUBAI, DUBAI, UNITED ARAB EMIRATES, August 6, 2025 /EINPresswire.com/ -- Guildhall, the region’s …
New Agreement Brings Breakthrough Dyslipidemia Treatment to Saudi Arabia and MEA
EIN Presswire
·
August 6, 2025
Strategic partnership between Jamjoom Pharma and Althera Laboratories will bring an innovative, dual-action cholesterol therapy to the region. DUBLIN, DUBLIN, IRELAND, August 6, 2025 /EINPresswire.com/ -- Jamjoom Pharma, a leading Saudi pharmaceutical …
Vaxart to Host Second Quarter 2025 Business Update and Financial Results Conference Call on August 13
GlobeNewswire
·
August 6, 2025
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) today announced it will provide a business update and report financial results for the second quarter ended June 30, 2025, …
Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 6, 2025
Initiated Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study with M4 positive allosteric modulator (PAM) NMRA-861, with data expected in the first quarter of 2026 Announces prioritization of obesity as lead indication for NMRA-215, a …
HilleVax Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 6, 2025
BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the quarter ended June 30, 2025. Second …
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results
GlobeNewswire
·
August 6, 2025
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, …
PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
GlobeNewswire
·
August 6, 2025
SAN JOSE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited …
Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress
GlobeNewswire
·
August 6, 2025
Strong execution of two ongoing Phase 3 trials of daraxonrasib; for RASolute 302, company is winding down enrollment in U.S. and expects to complete enrollment of the trial this year FDA Breakthrough Therapy Designations granted for two RAS(ON) inhibitors …
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
August 6, 2025
BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by …
Keros Therapeutics Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 6, 2025
LEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of …
Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
GlobeNewswire
·
August 6, 2025
Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts Aleniglipron clinical development program expanded to optimize competitive positioning and Phase 3 program Oral small …